Pliant Therapeutics (PLRX) Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings or view top-rated stocks.

11 equities research analysts have issued 1 year target prices for Pliant Therapeutics' stock. Their PLRX share price forecasts range from $33.00 to $63.00. On average, they expect the company's stock price to reach $48.36 in the next twelve months. This suggests a possible upside of 203.4% from the stock's current price.
View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts.

Pliant Therapeutics' stock was trading at $19.33 at the beginning of the year. Since then, PLRX stock has decreased by 17.5% and is now trading at $15.94.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PLRX earnings forecast.

Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.03. The company earned $0.25 million during the quarter, compared to the consensus estimate of $1.10 million. Pliant Therapeutics had a negative net margin of 2,872.79% and a negative trailing twelve-month return on equity of 33.10%.

ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

(PLRX) raised $90 million in an IPO on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX."

Pliant Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.45%), Deep Track Capital LP (6.77%), Casdin Capital LLC (2.84%), Polar Capital Holdings Plc (2.74%), Great Point Partners LLC (2.59%) and Franklin Resources Inc. (2.54%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette.
View institutional ownership trends.

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PLRX stock can currently be purchased for approximately $15.94.

Pliant Therapeutics (NASDAQ:PLRX) has a market capitalization of $953.69 million and generates $9.69 million in revenue each year. The company earns $-123,320,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

The company employs 155 workers across the globe.

Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is pliantrx.com. The company can be reached via phone at 650-481-6770 or via email at ir@pliantrx.com.